NYMX News Alert Nymox Pharmaceutical Corp (NYMX) 0.38 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Nymox Pharmaceutical Corp (NYMX) 0.38 $NYMX

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Nymox Pharmaceutical Corporation to Contact Brower Piven Before the January 26, 2015 Lead Plaintiff Deadline in Class Action Lawsuit -- NYMX
GlobeNewswire - Mon Dec 22, 7:18PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Nymox Pharmaceutical Corporation ("Nymox" or the "Company" (Nasdaq:NYMX) common stock during the period between January 31, 2011 and November 2, 2014, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until January 26, 2015 to seek appointment as lead plaintiff.
NYMX: 0.38 (unch)

Nymox concludes USD1.07m convertible debenture financing
M2 - Fri Dec 19, 7:04AM CST
Biopharmaceutical company Nymox Pharmaceutical (NasdaqCM:NYMX) revealed on Thursday the completion of its USD1.07m financing, with Cantone Asset Management as the exclusive agent.
NYMX: 0.38 (unch)

Nymox Announces $1.07 Million Financing
GlobeNewswire - Thu Dec 18, 11:57AM CST
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today the closing of U.S. $1.07 million in financing, consisting of a 3 year term convertible debenture at 6% with conversion at $0.53. The proceeds will be used as additional funding for the Company's activities in the next year. Cantone Asset Management LLC of Tintin Falls NJ served as exclusive agent for the convertible offering.
NYMX: 0.38 (unch)

EQUITY ALERT: Rosen Law Firm Reminds Nymox Pharmaceutical Corporation Investors of Important Class Action Deadline -- NYMX
GlobeNewswire - Fri Dec 12, 3:04PM CST
The Rosen Law Firm reminds purchasers of Nymox Pharmaceutical Corporation common stock (Nasdaq:NYMX) during the period from January 31, 2011 through November 2, 2014, of the important January 26, 2015 lead plaintiff deadline in the class action.
NYMX: 0.38 (unch)

SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Nymox Pharmaceutical Corporation and Its Board of Directors and a Lead Plaintiff Deadline of January 26, 2015 -- NYMX
GlobeNewswire - Thu Dec 11, 2:09PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Nymox Pharmaceutical Corporation ("Nymox" or the "Company" (Nasdaq:NYMX) securities between January 31, 2011 and November 2, 2014.
NYMX: 0.38 (unch)

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Nymox Pharmaceutical Corporation To Contact Brower Piven Before The January 26, 2015 Lead Plaintiff Deadline In Class Action Lawsuit
Business Wire - Tue Dec 09, 9:00PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Nymox Pharmaceutical Corporation ("Nymox" or the "Company" (Nasdaq: NYMX) common stock during the period between January 31, 2011 and November 2, 2014, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until January 26, 2015 to seek appointment as lead plaintiff.
NYMX: 0.38 (unch)

Law Offices of Marc S. Henzel Announces Securities Class Action Periods
PR Newswire - Mon Dec 08, 8:11AM CST
The Law Offices of Marc S. Henzel (www.henzellaw.com) a firm focusing on shareholder litigation, gives notice to purchasers of the following securities for the following class periods:
MOLG: 2.92 (+0.03), AVNR: 16.91 (+0.01), HE: 33.35 (+0.17), ADHD: 4.00 (+0.24), NYMX: 0.38 (unch), SDRL: 11.90 (+0.04), SNY: 46.35 (+0.50), AMRI: 15.19 (+0.05), CIE: 8.79 (-0.25)

Escherichia Coli Infections - Pipeline Review, H2 2014
M2 - Mon Dec 08, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/dtjjhp/escherichia_coli) has announced the addition of the "Escherichia Coli Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Escherichia Coli Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Escherichia Coli Infections and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Escherichia Coli Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Escherichia Coli Infections pipeline depth and focus of Indication therapeutics Companies Mentioned: - Adenium Biotech ApS - Arsanis Biosciences GmbH - AvidBiotics Corp. - Bellus Health Inc. - Bioorganic Research and Services S.A. - Cellceutix Corporation - Chiesi Farmaceutici SpA - ConjuGon, Inc. - Debiopharm International S.A. - Evolva SA - GangaGen Inc. - Genentech, Inc. - GlycoVaxyn AG - Immuron Limited - Melinta Therapeutics, Inc - Northern Antibiotics Oy - Nosopharm SAS - NovaBay Pharmaceuticals, Inc. - Novabiotics Ltd - Nymox Pharmaceutical Corporation - Pherecydes Pharma SA - Phico Therapeutics Ltd. - Procarta Biosystems Ltd - Sanofi Pasteur SA - Sealife PHARMA GMBH - Sequoia Sciences, Inc. - Soligenix, Inc. - Spider Biotech - Syntiron LLC - Trana Discovery, Inc. For more information visit http://www.researchandmarkets.com/research/dt...ichia_coli
NYMX: 0.38 (unch)

Lifshitz & Miller Law Firm Announces Investigation of Avanir Pharmaceuticals, Inc., Carbonite, Inc., Casey's General Stores, Inc., Nymox Pharmaceutical Corporation, Puma Biotechnology Inc., RealD Inc., and Spansion, Inc.
PR Newswire - Thu Dec 04, 12:21PM CST
Avanir Pharmaceuticals, Inc.
CARB: 14.54 (+0.94), AVNR: 16.91 (+0.01), RLD: 11.35 (+0.02), NYMX: 0.38 (unch), CASY: 89.15 (+0.12), PBYI: 189.96 (+0.12), CODE: 34.55 (+0.64)

Robbins Arroyo LLP: Nymox Pharmaceutical Corporation (NYMX) Misled Shareholders According to a Recently Filed Class Action
GlobeNewswire - Mon Dec 01, 7:07PM CST
Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Nymox Pharmaceutical Corporation (Nasdaq:NYMX) has filed a federal securities fraud class action complaint in the U.S. District Court for the Southern District of New Jersey. The complaint alleges that the company and certain of its officers and directors violated the Securities Act of 1934 in connection with Nymox's misstatements regarding the viability of its proprietary drug NX-1207 for the treatment of benign prostatic hyperplasia ("BPH" . Nymox is engaged in the research and development of therapeutics and diagnostics, with an emphasis on products for the unmet needs of the aging population.
NYMX: 0.38 (unch)

Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Nymox Pharmaceutical Corporation -- NYMX
GlobeNewswire - Wed Nov 26, 6:00PM CST
Gainey McKenna & Egleston announces that a class action lawsuit has been filed in the United States District Court for the District of New Jersey, on behalf of all persons who purchased or otherwise acquired Nymox Pharmaceutical Corporation ("Nymox" or the "Company" (Nasdaq:NYMX) securities during the period between January 31, 2011 through November 2, 2014, inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" .
NYMX: 0.38 (unch)

INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Nymox Pharmaceutical Corporation (NYMX) to Contact the Firm
Marketwired - Wed Nov 26, 3:44PM CST
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Nymox Pharmaceutical Corporation ("Nymox" or the "Company" (NASDAQ: NYMX) of the January 26, 2015 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against Nymox and the president and founder of the Company.
NYMX: 0.38 (unch)

Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information
PR Newswire - Wed Nov 26, 1:31PM CST
Cohen, Placitella & Roth, PC is investigating potential claims on behalf of investors who purchased Nymox Pharmaceutical Corporation ("Nymox" or "Company" (NASDAQ: NYMX) during the period from January 31, 2011 through November 2, 2014 ("Class Period" . The investigation concerns whether Nymox and certain of its officers and directors publically disseminated materially false and/or misleading information in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, promulgated thereunder.
NYMX: 0.38 (unch)

INVESTOR ALERT: The Rosen Law Firm Announces Filing of Securities Class Action Against Nymox Pharmaceutical Corporation to Recover Investor Losses - NYMX
GlobeNewswire - Tue Nov 25, 1:18PM CST
The Rosen Law Firm announces that a class action lawsuit has been filed on behalf of purchasers of Nymox Pharmaceutical Corporation common stock (Nasdaq:NYMX) during the period from January 31, 2011 through November 2, 2014. The class action seeks to recover investors' losses under the federal securities laws.
NYMX: 0.38 (unch)

Class Action Lawsuit Filed Against Nymox Pharmaceutical Corporation and Paul Averback by Law Offices Bernard M. Gross, P.C. -- NYMX
GlobeNewswire - Tue Nov 25, 11:38AM CST
Law Offices Bernard M. Gross, P.C. filed a class action lawsuit in the United States District Court, District of New Jersey, 14-cv-07331, on behalf of purchasers of NYMOX common stock between January 31, 2011 and November 2, 2014. This matter is pending before the Honorable Jose L. Linares.
NYMX: 0.38 (unch)

Nymox incurs lower net loss of USD688,206 for Q3 2014
M2 - Mon Nov 17, 6:53AM CST
Diagnostics company Nymox Pharmaceutical (NasdaqCM:NYMX) on Friday declared a net loss of USD688,206 (USD0.02 per share) for the third quarter of 2014.
NYMX: 0.38 (unch)

Nymox Pharma EPS of -$0.02
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 9:14AM CST

NYMX: 0.38 (unch)

Nymox Reports Third Quarter 2014 Financial Results
GlobeNewswire - Fri Nov 14, 9:00AM CST
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the third quarter of 2014. Nymox reported net losses of $688,206, or $0.02 per share, for the quarter and $4,101,293, or $0.12 per share, for the nine months ended September 30, 2014, compared to net losses of $1,020,387, or $0.03 per share, for the quarter and $3,591,682, or $0.11 per share, for the nine months ended September 30, 2013. The decrease in net losses for the third quarter in 2014 compared to 2013 is mainly due to a reduction of $515,417 in clinical trial expenditures related to NX-1207 studies. The increase in net losses for the nine months ended September 30, 2014 compared to 2013 is mainly due to an increase of stock compensation charges of $1,261,367 relating to the grant of options offset by a decrease of $1,023,460 in clinical trial expenditures.
NYMX: 0.38 (unch)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

California Stone Ban Puts a Hidden Worker Toll in View

Updated Category News Views 42

Countertops are supposed to finish a kitchen, not quietly wreck the lungs of the people cutting them. Yet California's move toward prohibiting the fabrication and installation of artificial stone containing more than 1% crystalline silica puts an ugly, long-running occupational-health problem in plain sight. This is not a story that calls for chest-thumping market talk....

Continue Reading
Water Damage Coverage Has More Traps Than Homeowners Think

Updated Category News Views 29

A wet basement does not care one bit whether the water arrived dramatically or dripped in for months. That ugly distinction, though, can decide whether a homeowner has an insurance claim or a repair bill that lands with a thud. Kathy Thurmond-Edwards, an insurance expert in Memphis, Tennessee, lays out the dividing lines plainly: sudden pipe failures may be treated very...

Continue Reading
ACP's 1-for-4 Split Raises Price, Not Investor Value Yet

Updated Category News Views 68

Four ACP shares are about to become one, and the calculator crowd is liable to make a mountain out of a bookkeeping move. abrdn Income Credit Strategies Fund will execute a 1-for-4 reverse split before the opening bell on December 7, 2026. The quoted share price should rise by roughly four times, but the economic stake held by an investor does not magically get bigger...

Continue Reading
Surf City Seasons Put Vacation Rental Timing in Focus

Updated Category News Views 28

Summer’s Calendar Does the Talking School bells, not seagulls, appear to set the pace for Surf City’s rental market. Chris Rackley’s seasonal guide makes a pretty grounded point: the “best” time to visit Surf City, North Carolina, is not some universal magic week on a postcard. It depends on whether a traveler needs peak beach weather, wants elbow room, or...

Continue Reading
Home Nursing Plans Need Clarity Before the Next Crisis

Updated Category News Views 71

A medication change scribbled on a loose sheet can become a very long night. That is the unglamorous truth behind the discussion from Michael and Marsha Reda of Aurora Home Care in Williamsville, New York: long-term home nursing care depends on a plan people can actually follow when the household is tired, worried, and juggling too much. Their perspective, featured by...

Continue Reading
Cash Flow Discipline Is Where Business Growth Gets Real

Updated Category News Views 73

A full order book can still leave a company gasping at payroll. That is the unglamorous point behind the Nov. 20, 2026, HelloNation piece featuring Kimberly Furrh of Furrh & Associates PC in Lawton, Oklahoma. Owners love to talk about sales because sales are visible, flattering and easy to celebrate. Cash is less theatrical. It is also the thing that keeps the lights on...

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 116

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 110

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
Rosalind Franklin University’s $23.8M Scholarship Win

Updated Category News Views 80

Twenty-three million dollars can disappear fast in graduate health education, which is exactly why Rosalind Franklin University’s campaign result deserves more than a polite round of applause. The university’s five-year Empowering Scholars effort closed in June 2026 with $23,836,272 raised, clearing its $20 million target by roughly 19%. In a world where institutions...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 61

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading

Top 5 Most Recently Viewed Articles

Thompson Thrift Secures Over $255 Million in New Funding

Updated Category News Views 303

Thompson Thrift Closes Major Funding Round for Multifamily Developments Thompson Thrift, a well-known real estate company, recently announced a significant achievement in closing its 2025 multifamily development fund. This limited partnership offering successfully raised over $255 million in capital commitments, exceeding its original target of $230 million. The funds aim...

Continue Reading
Buyglobal's Summer Sale Offers Outdoor Essentials and Deals

Updated Category News Views 25

Buyglobal's Summer Event: A Sunny Boost for Backyard Living Summer's rolling in, and Buyglobal is gearing up to help you transform those backyard spaces into your very own oasis. This ain't your average sale event—this is Buyglobal jumping headfirst into the season with a curated lineup that's all about making the most of the outdoors. They rolled out their...

Continue Reading
Tony Fadell Champions Plumerai's Tiny AI for Smart Homes

Updated Category News Views 201

Transforming Smart Home Security with Tiny AI In the realm of innovative technology, Tony Fadell, co-creator of the iPod and Nest founder, recognizes the groundbreaking work Plumerai is doing in the field of artificial intelligence. Their emphasis on Tiny AI technology is heralded as a pivotal shift that aims to democratize AI for everyday use, particularly in smart home...

Continue Reading
Glenn Pushis Takes Action: Sells $172K in Steel Dynamics Shares

Updated Category News Views 183

Understanding Insider Actions at Steel Dynamics A notable insider transaction has come to light involving Glenn Pushis, the Senior Vice President at Steel Dynamics (NASDAQ: STLD). This transaction was detailed through an SEC filing that disclosed a significant sell-off of shares worth $172,043. Details of the Sell-Transaction According to the Form 4 filing submitted to...

Continue Reading
SCF Partners Strengthens Market Position with New Acquisition

Updated Category News Views 228

SCF Partners' Strategic Acquisition of Newpark Fluids Systems SCF Partners is making waves with its recent acquisition of Newpark Fluids Systems, a well-respected name in the oil, gas, and geothermal fluids industry. This strategic decision underscores SCF's dedication to broadening its service offerings and expanding its market presence. Newpark Fluids Systems has built...

Continue Reading